Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bludenz – page 5

67 clinical trials in Bludenz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bludenz at a glance
67
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

67 trials in Bludenz

Open in trial search

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astrazeneca AB

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Astrazeneca AB

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bludenz

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on Chronic Obstructive Pulmonary Disease (COPD) management, specifically targeting patients with moderate to severe cases who experience frequent exacerbations.

  • Disease Focus: Moderate to Very Severe COPD
  • Key Investigation: Exacerbation Management
  • Patient Profile: Those with Elevated Blood Eosinophils

The research evaluates the effectiveness of benralizumab in reducing COPD exacerbations, representing a significant advancement in respiratory therapeutics for patients with frequent disease flare-ups.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.